CNSY CERENOME, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1095981 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-32.9%
TTM net income YoY-47.4%
TTM EPS YoY143.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-832.6%
Net margin-859.5%
FCF margin-813.5%
EBITDA margin-817.7%
Returns
ROE-1,468.0%
ROA-196.4%
ROIC (approx.)—
Asset turnover0.23x
Leverage & solvency
Liabilities / assets107.6%
Debt / equity—
Current ratio0.61x
Interest coverage-815.92x
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-19.6%
Payout ratio—
Capex / revenue39.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $5.21M | $5.82M |
| R&D expense | $8.38M | $10.58M |
| SG&A expense | $12.13M | $9.94M |
| Operating income | -$15.30M | -$14.70M |
| Interest expense | $548,000 | $179,000 |
| Pretax income | -$22.39M | -$12.98M |
| Income tax | $0 | $0 |
| Net income | -$22.39M | -$12.98M |
| EBITDA | -$14.85M | -$13.82M |
| EPS (basic) | -0.29 | -1.95 |
| EPS (diluted) | -0.29 | -2.34 |
| Weighted avg. shares (diluted) | 77.80M | 7.70M |
| Balance sheet | ||
| Cash & equivalents | $4.26M | $76,000 |
| Short-term investments | $4.36M | $3.53M |
| Current assets | $14.85M | $5.26M |
| PP&E, net | $257,000 | $448,000 |
| Goodwill | $372,000 | $372,000 |
| Intangibles | $333,000 | $469,000 |
| Total assets | $16.32M | $6.63M |
| Current liabilities | $12.31M | $15.55M |
| Total liabilities | $12.33M | $15.58M |
| Shareholders' equity | $4.00M | -$8.95M |
| Shares outstanding | 5.55M | 5.90M |
| Cash flow statement | ||
| Operating cash flow | -$20.77M | -$10.55M |
| Capital expenditure | $67,000 | $146,000 |
| Free cash flow | -$20.84M | -$10.70M |
| Investing cash flow | -$854,000 | -$4.11M |
| Financing cash flow | $30.31M | $6.19M |
| Depreciation & amortization | $445,000 | $872,000 |
| Stock-based compensation | $1.54M | $550,000 |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.